基于基因检测的26例晚期非小细胞肺癌患者化疗疗效观察  

Clinical observation of 26 advanced non-small cell lung cancer patients with chemotherapy based on genetic testing

作　　者：石林[1] 陈嘉[1] 沈波[1] 孙晓峰[1] 陈凌翔[1] 周青[1] 

机构地区：[1]南京医科大学附属江苏省肿瘤医院肿瘤内科,江苏南京210009

出　　处：《实用临床医药杂志》2012年第23期25-27,共3页Journal of Clinical Medicine in Practice

基　　金：江苏省卫生厅科研基金(Z200902);中国高校医学期刊临床专项资金(11220255)

摘　　要：目的观察基于肺癌化疗预测因子指导下的非小细胞肺癌(NSCLC)化疗疗效。方法 26例NSCLC患者标本行切除修复交叉互补基因1(ERCC1)、核糖核苷酸还原酶M1(RRM1)、β-微管蛋白(β-tubulin)和胸苷酸合成酶(TS)基因检测。根据检测结果选择化疗方案,每例患者至少完成2个周期化疗后评估客观疗效、无进展生存时间(PFS)及毒性反应。结果客观缓解率(ORR)为34.6%,疾病控制率(DCR)为57.7%。其中,一线治疗ORR为60%,DCR为70%;二线治疗ORR为30%,DCR为60%。总体PFS为4.9个月;其中一线、二线和三线PFS分别为6.7个月、4.5个月和1.5个月。毒性反应以血液学及消化道反应为主。结论根据肺癌化疗预测因子制定的化疗方案可提高NSCLC一线和二线治疗的疗效,延长一线治疗的PFS,毒副作用可耐受。Objective To observe the efficacy of non - small cell lung cancer （NSCLC） chemotherapy based on predictor factors of lung chemotherapy. Methods The specimens of 26 NSCLC patients were detected with ERCC1, RRM1, β- tubulin and TS. The chemotherapy regi- mens were selected based on the genetic testing results, and every patient underwent assessments such as objective effect, progression - free survival （PFS） and toxicity until he or she finished 2 cy- cles of chemotherapy at least. Results The objective response rate （ORR） was 34.6%, the disease control rate （DCR） was 57.7%. In first- line therapy, ORR and I）CR was 60% and 70% respec- tively. In second - line therapy, ORR and DCR was 30 % and 60 % individually. Total PFS was 4. 9 months. The PFS of first, second and third - line therapy was 6.7, 4.5 and 1.5 months respec- tively. The toxic reactions were gastrointestinal and hematology reactions. Conclusion The chemotherapy regimen based on predictor factors of lung chemotherapy can improve efficacy of both first and second - line therapy, and prolong the PFS in first - line therapy in NSCLC. The side ef- fects are tolerable.

关 键 词：基因检测 非小细胞肺癌 切除修复交叉互补基因1 核糖核苷酸还原酶M1 Β-微管蛋白 胸苷酸合成酶 

分 类 号：R730.43[医药卫生—肿瘤]